Chemotherapy-induced myelosuppression worsens fatigue and daily function, drives dose delays, and may limit future treatment options—making early management critical.
Amanda Edmond, PA-C
Advertisement
Articles by Amanda Edmond, PA-C
Learn how proactive myeloprotection, including trilaciclib, helps manage myelosuppression and keep chemo on track in extensive-stage SCLC.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
European Commission Approves First-Line Dato-DXd for Immunotherapy-Ineligible Metastatic TNBC
3
Dr Choueiri on Safety Data From the Phase 3 LITESPARK-022 Trial in ccRCC
4
Baseline and On-Treatment QOL Improvements Track With Survival Benefits With Belzutifan or Everolimus in ccRCC
5